ClinicalTrials.gg
CompletedNCT03353922Updated Feb 1, 2022Results posted

Driving Simulation to Assess Non-Sedative Effects of Tolperisone

A Phase 1 interventional study of Cyclobenzaprine 10 Mg Oral Tablet and Placebo Oral Tablet in Driving Impaired, sponsored by Neurana Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-01.

Sponsored by Neurana Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2017, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.

Read the detailed description

This will be a randomized, placebo-controlled, multiple-dose 3-way cross-over study of the safety and cognitive effects of multiple doses of 150 mg tolperisone administered TID in 30 male and female healthy volunteers. Treatment groups include 450 mg tolperisone (i.e., 150 mg administered three times daily), 30 mg cyclobenzaprine (i.e., 10 mg administered three times daily), and placebo. Subjects will receive 3 days of each treatment.

Subject participation will be approximately 3 weeks as outpatients with 3 days each week as overnight clinic participants.

In this crossover study, treatment effects will be assessed following the second initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).

Subjects will be dosed on the morning of Day 1. Approximately one hour after the second dose on Day 1, subjects will be administered the cognitive test, followed by the driving simulator examination.

On the morning of Day 2, prior to dosing, subjects will be readministered the cognitive test and driving examination to assess residual next day effects.

Subjects will repeat cognitive testing and the driving examination on the morning of Day 3, after administration of the AM study medication, to evaluate the cumulative effects of 3 days of dosing.

02

Conditions studied

  • Driving Impaired

Keywords

  • cognitive function
03

In context

Lead sponsor

Neurana Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All healthy volunteer subjects must be in general good health based on screening physical examination (defined as the absence of any abnormalities), medical history, 12-lead , and clinical laboratory values (hematology, serum chemistry and urinalysis).
  2. All subjects must be capable of understanding and complying with the protocol and have signed the document. Female subjects of must sign the Women of Childbearing Potential Addendum to the informed consent form.
  3. Subjects are required to have a (BMI) of 18 to 32 kg/m2, inclusive, at Screening.
  4. Subject must be able to reliably perform study assessments (i.e., SDLP no higher than 1 standard deviation greater than the mean for normal healthy adults completing the CVDA practice scenario; and number correct on CogScreen Symbol Digit Coding no less than 1 standard deviation below the mean for healthy adults in the 21-55 year age range); demonstrates the ability to understand task instructions (in English), and be physically capable (e.g., adequate manual dexterity, vision, and hearing), cognitively capable and motivated to perform study tasks.
  5. Subject must possess a valid driver's license and be an active driver, and have driven a minimum of 10,000 miles (about 16,000 km) per year for the previous 3 years.
  6. Subject must also demonstrate simulator sickness questionnaire scores which are not indicative of simulator sickness as defined in the driving simulation operations manual.
  7. Subject must have a regular sleep pattern, not be engaged in shift-work, and in general, have at least 7 hours of sleep each night (bedtime occurs between 21:00 and 24:00 hours).
  8. Subject has a score \< 10 on the Epworth Sleepiness Scale (ESS).
  9. Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have any unstable medical abnormality, chronic disease or a history of a clinically significant abnormality of the cardiovascular, gastrointestinal, respiratory, hepatic, or renal systems.
  2. Subjects who test positive at screening for surface antigen, antibody or have a history of a positive result.
  3. Subjects who are known to be seropositive or test positive at Screening for (HIV).
  4. Female subjects who are pregnant or lactating.
  5. Subjects who have a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
  6. A history within 2 years of, or current treatment for a sleeping disorder (including excessive snoring, obstructive sleep apnea), or a chronic painful condition that interferes with the subject's sleep.
  7. A history of difficulty in falling asleep or staying asleep in the previous 3 months, that is considered clinically significant by the investigator.
  8. Subjects who have a history or diagnosis of any of the following conditions:

    1. Primary or secondary insomnia
    2. Narcolepsy
    3. Cataplexy (familial or idiopathic)
    4. Circadian Rhythm Sleep Disorder
    5. Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and rapid eye movement behavior disorder
    6. Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome)
    7. Periodic Limb Movement Disorder
    8. Restless Legs Syndrome
    9. Primary Hypersomnia
    10. Excessive Daytime Sleepiness (EDS)
    11. Subject has visual or auditory impairment which in the opinion of the investigator would interfere with study related procedures or study conduct.
  9. Subjects expected to use any other medication or dietary supplement to promote sleep including over-the-counter sleep medications, during their participation in the study.
  10. Subjects who have participated in any study within 30 days prior to screening or are currently participating in another clinical trial.
  11. Subjects who have had a recent history (less than 2 years before entering the study) of drug or alcohol abuse, or current positive urine drug screen. Alcohol abuse is defined as current consumption of more than three alcoholic beverages per day.
  12. Subjects who have a history of allergic reaction to tolperisone or cyclobenzaprine or any components of these study medications.
  13. Use of psychoactive prescription or non-prescription medications, psychoactive nutritional supplements or herbal preparations within 2 weeks or 5 half-lives (whichever is longer) of admission to the Clinical Research Unit (CRU) on Day 1.
  14. Presence of a medical or psychiatric condition which could jeopardize the safety of the subject or validity of study results
  15. Subjects who consume excessive amounts of coffee, tea, cola, or other caffeinated beverages per day. Excessive amount is defined as greater than 6 servings per day (where 1 serving is approximately equivalent to 120 mg of caffeine).
  16. Subjects who will be working a night shift within 1 week of a visit.
  17. Subject who have traveled across 1 or more time zones (transmeridian travel) in the last 2 weeks prior to randomization or is expected to travel across 1 or more time zones during the study.
  18. Current smoker (>10 cigarettes or eCigarettes, 3 cigars, or 3 pipes per day) and unwilling to refrain from smoking while confined to the CRU for periods of 3 days.
  19. Subjects who have an inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator or designee.
  20. Subjects who are a staff member or relative of a staff member.
  21. Inability or unwillingness to use adequate (as defined in item 10 of the Inclusion Criteria) during and for 1 month following completion of the study.
  22. Has a positive screen for alcohol or other drugs of abuse (amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Tolperisone HCl 150 mg

    150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days

    Drug: Cyclobenzaprine 10 Mg Oral Tablet · Drug: Placebo Oral Tablet

  • Placebo comparator
    Placebo Oral Tablet

    sugar pills administered by mouth every 8 hours for 3 days

    Drug: Cyclobenzaprine 10 Mg Oral Tablet · Drug: Placebo Oral Tablet

  • Active comparator
    Cyclobenzaprine 10 mg oral tablet

    10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days

    Drug: Placebo Oral Tablet

Interventions

  • cyclobenzaprine 10 mg tablets

    Also known as: Flexeril

  • DrugPlacebo Oral Tablet

    sugar pill

    Also known as: tolperisone matching placebo

06

What researchers measure

Primary outcomes

  1. Standard Deviation of Lateral Position (SDLP)

    In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).

    Time frame: at time of peak concentration of drug (Tmax) on Day 1

Secondary outcomes

  1. Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect

    SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment

    Time frame: in the morning predose on Day 2 following nighttime dosing

  2. Sleepiness Endpoint Karolinska Sleepiness Scale KSS

    assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy

    Time frame: at Tmax on Day 1

  3. Steady State Standard Deviation of Lateral Position (SDLP) Day 3

    SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes

    Time frame: Day 3

07

Results

Posted Oct 20, 2020

Participant flow

Participant flow — Overall Study
MilestoneABC (Tolperisone, Cyclobenzaprine, Placebo)ACB (Tolperisone, Placebo, Cyclobenzaprine)BAC (Cyclobenzaprine, Tolperisone, Placebo)BCA (Cyclobenzaprine, Placebo, Tolperisone)CAB (Placebo, Tolperisone, Cyclobenzaprine)CBA (Placebo, Cyclobenzaprine, Tolperisone)
Started666656
Completed555556
Not completed111100
Withdrew: Withdrawal by subject101100
Withdrew: Adverse event010000

Outcome measures

PrimaryStandard Deviation of Lateral Position (SDLP)

In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).

Time frame:
at time of peak concentration of drug (Tmax) on Day 1
Reported as:
Mean · cm of deviation of lateral position
Standard Deviation of Lateral Position (SDLP)
cm of deviation of lateral positionTolperisone HCl 150 mgPlacebo Oral TabletCyclobenzaprine 10 mg Oral Tablet
Standard Deviation of Lateral Position (SDLP)29.3 ± 6.2529.7 ± 6.3738.6 ± 12.35
SecondaryStandard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect

SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment

Time frame:
in the morning predose on Day 2 following nighttime dosing
Reported as:
Mean · cm of deviation from lateral position
Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect
cm of deviation from lateral positionTolperisone HCl 150 mgPlacebo Oral TabletCyclobenzaprine 10 mg Oral Tablet
Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect29.6 ± 7.0829.9 ± 7.7135.1 ± 10.37
SecondarySleepiness Endpoint Karolinska Sleepiness Scale KSS

assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy

Time frame:
at Tmax on Day 1
Reported as:
Mean · units on a scale
Sleepiness Endpoint Karolinska Sleepiness Scale KSS
units on a scaleTolperisone HCl 150 mgPlacebo Oral TabletCyclobenzaprine 10 mg Oral Tablet
Sleepiness Endpoint Karolinska Sleepiness Scale KSS3.3 ± 1.963.4 ± 1.995.6 ± 2.44
SecondarySteady State Standard Deviation of Lateral Position (SDLP) Day 3

SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes

Time frame:
Day 3
Reported as:
Mean · cm deviation from lateral position
Steady State Standard Deviation of Lateral Position (SDLP) Day 3
cm deviation from lateral positionTolperisone HCl 150 mgPlacebo Oral TabletCyclobenzaprine 10 mg Oral Tablet
Steady State Standard Deviation of Lateral Position (SDLP) Day 329.8 ± 6.6829.6 ± 7.4631.7 ± 7.9

Adverse events

Collected over The total duration of study participation was approximately 4 weeks including screening to follow up.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolperisone HCl 150 mg0/33 (0%)0/33 (0%)15/33 (45.5%)
Placebo Oral Tablet0/31 (0%)0/31 (0%)12/31 (38.7%)
Cyclobenzaprine 10 mg Oral Tablet0/33 (0%)0/33 (0%)20/33 (60.6%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventTolperisone HCl 150 mgPlacebo Oral TabletCyclobenzaprine 10 mg Oral Tablet
somnolenceNervous system disorders5/332/3110/33
dizzinessNervous system disorders1/332/313/33
nauseaGastrointestinal disorders0/332/311/33
headacheNervous system disorders2/330/310/33
dry mouthGastrointestinal disorders0/330/312/33
abdominal painGastrointestinal disorders1/331/311/33
dyspepsiaGastrointestinal disorders0/331/310/33
upper respiratory infectionInfections and infestations0/331/310/33
insomniaPsychiatric disorders0/331/311/33
hyperhydrosisSkin and subcutaneous tissue disorders0/331/310/33

Baseline characteristics

Final analysis on per protocol population (n=33) instead of ITT (n=35) due to 2 subjects being mis-dosed

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years33
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female10
Male23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino10
Not Hispanic or Latino23
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American15
White17
More than one race0
Unknown or Not Reported0
BMI
BMI(kg/m2)All Study Participants
Mean25.012 ± 2.959
08

Study locations

2 sites
  • Collaborative Neuroscience Network
    Long Beach, California 92845, United States
  • NeuroTrials Research
    Atlanta, Georgia 30342, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Dec 2017, 4 months.

Results were first posted in Oct 2020, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 27, 2017
StartActual
Jul 31, 2017
Primary completionActual
Dec 6, 2017
CompletionActual
Jan 30, 2018
Results first posted
Oct 20, 2020
Last update
Feb 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03353922
Lead sponsor
Neurana Pharmaceuticals, Inc.
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
Nov 27, 2017
Start date
Jul 31, 2017
Primary completion
Dec 6, 2017
Completion
Jan 30, 2018
Results posted
Oct 20, 2020
Last update
Feb 1, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion